EPO and glaucoma: Adeno-associated virus (AAV) vectors are currently the predominant choice for glaucoma gene therapy delivery, encoding genes such as BDNF, EPO, and NRF2, enabling uncontrolled expression of target genes in AAV-transduced cells in both in vivo and in vitro models.